Some drug companies try to shift blame for higher prices by blaming the PBMs who negotiate rebates and discounts on behalf of employers, unions, and government programs that offer coverage.
This makes no sense. Would anyone believe a TV manufacturer if it said its price hikes were due to aggressive discounting and rebating by a big box retailer?
Furthermore, a new study debunks the notion that the prices drugmakers set are contingent on the rebates they negotiate with pharmacy benefit managers (PBMs). Ironically, many higher priced drugs involve little or no such rebates.